Bausch + Lomb Shares Rise Premarket on Positive Trial for Glaucoma Treatment

Dow Jones03-23

By Adriano Marchese

Shares of Bausch + Lomb rose in premarket trading Monday after the company said that data from its glaucoma procedure trials was positive.

Shares in New York traded 5% higher ahead of the morning bell at $16.51.

The eye-health company said that both primary effectiveness endpoints were met for its ELIOS procedure, an implant-free process that uses excimer laser technology to treat glaucoma.

Glaucoma is a group of eye diseases that damage the optic nerve connecting the eye to the brain.

The company said the most recent 24-month results from the pivotal U.S. clinical trial showed that there was statistically significant and clinically meaningful intraocular pressure reduction following the treatment.

ELIOS is currently under development in the U.S. and hasn't been reviewed by the Food and Drug Administration for safety or effectiveness.

The procedure has been available in Europe for several years, the company said, with positive results from the 850 eyes treated.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

March 23, 2026 07:43 ET (11:43 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621083767?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 19:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621083767","market":"other","top_or_hot":-1,"title":"Bausch + Lomb Shares Rise Premarket on Positive Trial for Glaucoma Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Bausch + Lomb rose in premarket trading Monday after the company said that data from its glaucoma procedure trials was positive. \n</p>\n<p>\n  Shares in New York traded 5% higher ahead of the morning bell at $16.51. \n</p>\n<p>\n  The eye-health company said that both primary effectiveness endpoints were met for its ELIOS procedure, an implant-free process that uses excimer laser technology to treat glaucoma. \n</p>\n<p>\n  Glaucoma is a group of eye diseases that damage the optic nerve connecting the eye to the brain. \n</p>\n<p>\n  The company said the most recent 24-month results from the pivotal U.S. clinical trial showed that there was statistically significant and clinically meaningful intraocular pressure reduction following the treatment. \n</p>\n<p>\n  ELIOS is currently under development in the U.S. and hasn't been reviewed by the Food and Drug Administration for safety or effectiveness. \n</p>\n<p>\n  The procedure has been available in Europe for several years, the company said, with positive results from the 850 eyes treated. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 23, 2026 07:43 ET (11:43 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bausch + Lomb Shares Rise Premarket on Positive Trial for Glaucoma Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBausch + Lomb Shares Rise Premarket on Positive Trial for Glaucoma Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-23 19:43</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Bausch + Lomb rose in premarket trading Monday after the company said that data from its glaucoma procedure trials was positive. \n</p>\n<p>\n  Shares in New York traded 5% higher ahead of the morning bell at $16.51. \n</p>\n<p>\n  The eye-health company said that both primary effectiveness endpoints were met for its ELIOS procedure, an implant-free process that uses excimer laser technology to treat glaucoma. \n</p>\n<p>\n  Glaucoma is a group of eye diseases that damage the optic nerve connecting the eye to the brain. \n</p>\n<p>\n  The company said the most recent 24-month results from the pivotal U.S. clinical trial showed that there was statistically significant and clinically meaningful intraocular pressure reduction following the treatment. \n</p>\n<p>\n  ELIOS is currently under development in the U.S. and hasn't been reviewed by the Food and Drug Administration for safety or effectiveness. \n</p>\n<p>\n  The procedure has been available in Europe for several years, the company said, with positive results from the 850 eyes treated. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 23, 2026 07:43 ET (11:43 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2621083767","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621083767","pubTimestamp":1774266180,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Bausch + Lomb rose in premarket trading Monday after the company said that data from its glaucoma procedure trials was positive.Shares in New York traded 5% higher ahead of the morning bell at $16.51.The eye-health company said that both primary effectiveness endpoints were met for its ELIOS procedure, an implant-free process that uses excimer laser technology to treat glaucoma.Glaucoma is a group of eye diseases that damage the optic nerve connecting the eye to the brain.The company said the most recent 24-month results from the pivotal U.S. clinical trial showed that there was statistically significant and clinically meaningful intraocular pressure reduction following the treatment.ELIOS is currently under development in the U.S. and hasn't been reviewed by the Food and Drug Administration for safety or effectiveness.The procedure has been available in Europe for several years, the company said, with positive results from the 850 eyes treated.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"博士伦股价因青光眼治疗试验积极而盘前上涨","themeId":"8603dabb40994e59ac78c04c930c0d49","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{},"content_text":"By Adriano Marchese \n\n\n \n\n\n  Shares of Bausch + Lomb rose in premarket trading Monday after the company said that data from its glaucoma procedure trials was positive. \n\n\n  Shares in New York traded 5% higher ahead of the morning bell at $16.51. \n\n\n  The eye-health company said that both primary effectiveness endpoints were met for its ELIOS procedure, an implant-free process that uses excimer laser technology to treat glaucoma. \n\n\n  Glaucoma is a group of eye diseases that damage the optic nerve connecting the eye to the brain. \n\n\n  The company said the most recent 24-month results from the pivotal U.S. clinical trial showed that there was statistically significant and clinically meaningful intraocular pressure reduction following the treatment. \n\n\n  ELIOS is currently under development in the U.S. and hasn't been reviewed by the Food and Drug Administration for safety or effectiveness. \n\n\n  The procedure has been available in Europe for several years, the company said, with positive results from the 850 eyes treated. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 23, 2026 07:43 ET (11:43 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":false,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621083767","isCrawlerRequest":true}